Header Ads Widget

First pill to successfully treat Covid ‘may be rolled out before Christmas’

An experimental Covid pill called molnupiravir could be offered to UK patients very soon (Picture: Reuters)

The first at-home Covid treatment could be offered to patients before Christmas to protect the most vulnerable from Omicron.

Health Secretary Sajid Javid is set to launch a national pilot of the Molnupiravir antiviral pill – also known as Lagevrio, the Telegraph reports.

Under the plans, the NHS was expected to deliver courses of the tablet to clinically vulnerable and immunosuppressed patients within as little as 48 hours of them testing positive.

It said hospitals and GPs had been told a series of Covid medicines delivery units were being established to ensure the treatment gets to patients as quickly as possible once it is confirmed they have the virus.

Last month, the UK became the first country in the world to license its use, a move described as a ‘game-changer’ by Mr Javid.

But just over a week ago, England’s chief medical officer Professor Chris Whitty warned its use may have to be reconsidered in the light of the emergence of Omicron.

He told a No 10 news conference: ‘I think we probably need to do a rethink of it just to make sure with the new variant, we’re targeting in the right direction.’

A Department of Health and Social Care spokesman said: ‘The UK has proven itself to be a world-leader in identifying and rolling out effective treatments for Covid-19, including through Government-backed national trials.

‘The Government’s antivirals taskforce was launched to identify treatments for UK patients who have been exposed to Covid-19 to take at home, stopping the infection spreading and speeding up recovery time.

‘There are a number of exciting opportunities in the pipeline and we will provide further details in due course.’

Get in touch with our news team by emailing us at webnews@metro.co.uk.

For more stories like this, check our news page.



from News – Metro https://ift.tt/3lBU2WO

Post a Comment

0 Comments